Table 2.
The associations between Clinicopathologic Characteristics and Endocrine Resistance in training Cohort.
| Endocrine Resistance | ||||
|---|---|---|---|---|
| Characteristics | No N = 414 (%) |
Yes N = 19 (%) |
Total N = 433 (%) |
P value |
| age | 0.870 | |||
| ≤35 | 26(6.3) | 1(5.3) | 27(6.2) | |
| 35–50 | 195(47.2) | 8(42.1) | 203(47.0) | |
| ≥50 | 192(46.5) | 10(52.6) | 202(46.8) | |
| ER∗ | 0.232 | |||
| Low | 79(19.1) | 6(31.6) | 85(19.6) | |
| High | 335(80.9) | 13(68.4) | 348(80.4) | |
| PR+ | 0.001 | |||
| Low | 173(41.8) | 15(78.9) | 188(43.4) | |
| High | 241(58.2) | 4(21.1) | 245(56.6) | |
| HER2∗∗ | 0.390 | |||
| Negative | 299(72.2) | 12(63.2) | 311(71.8) | |
| Positive | 115(27.8) | 7(36.8) | 122(28.2) | |
| Ki-67++ | 0.222 | |||
| Negative | 71(17.1) | 1(5.3) | 72(16.6) | |
| Positive | 343(82.9) | 18(94.7) | 361(83.4) | |
| Stage | 0.005 | |||
| I | 81(19.6) | 3(15.8) | 84(19.4) | |
| II | 280(67.6) | 7(36.8) | 287(66.3) | |
| III | 53(12.8) | 9(47.4) | 62(14.3) | |
| T stage | 0.274 | |||
| T1 | 95(22.2) | 3(15.8) | 95(21.9) | |
| T2 | 254(61.4) | 10(52.6) | 264(61.0) | |
| T3-4 | 68(16.4) | 6(31.6) | 74(17.1) | |
| N stage | 0.001 | |||
| N0 | 254(61.4) | 8(42.1) | 262(60.5) | |
| N1 | 121(29.2) | 3(15.8) | 124(28.6) | |
| N2-3 | 39(9.4) | 8(42.1) | 47(10.9) | |
| Grade | 0.019 | |||
| I-II | 243(58.7) | 6(31.6) | 249(57.5) | |
| III | 171(41.3) | 13(68.4) | 184(42.5) | |
| Pathologic type | 0.516 | |||
| IDC | 387(93.5) | 19(100.0) | 406(93.8) | |
| ILC | 17(4.1) | 0(0.0) | 17(3.9) | |
| Other | 10(2.4) | 0(0.0) | 10(2.3) | |
| Surgery | 0.010 | |||
| Mastectomy | 180(43.5) | 14(73.7) | 194(44.8) | |
| BCS | 234(56.5) | 5(26.3) | 239(55.2) | |
| Chemotherapy | 0.064 | |||
| No | 82(19.8) | 0(0) | 82(18.9) | |
| Yes | 332(80.2) | 19(100) | 351(81.1) | |
| Chemotherapy treatment | 0.670 | |||
| Anthracycline and paclitaxel-based | 231(69.6) | 15(78.9) | 246(70.1) | |
| Paclitaxel-based | 76(22.9) | 3(15.8) | 79(22.5) | |
| Anthracycline-based | 25(7.5) | 1(5.3) | 26(7.4) | |
| Endocrine therapy | 0.267 | |||
| Aromatase inhibitor | 186(44.9) | 11(57.9) | 197(45.5) | |
| Tamoxifen | 228(55.1) | 8(42.1) | 236(54.5) | |
| Ovarian function suppression | 0.562 | |||
| No | 279(78.2) | 14(87.5) | 293(78.6) | |
| Yes | 78(21.8) | 2(12.5) | 80(21.4) | |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor2; IDC, Invasive ductal carcinoma; ILC, Invasive lobular carcinoma; BCS, breast conserving surgery.
∗Cases where ≥10% of tumor cells stained positive for ER with immunohistochemistry (IHC) were considered high.
+Cases where ≥20% of tumor cells stained positive for PR with IHC were considered high.
∗∗Cases that showed either 3+ IHC staining or had gene copy number＞2.0 were considered HER2 positive.
++Cases where ≥14% of tumor cells stained positive for Ki-67 with IHC were considered positive.
P values of the comparison between Endocrine Resistance and non- Endocrine Resistance patients in training cohort were generated by χ2 test for categorical variables.